Monica Boirivant describes the work and the thinking behind her team’s demonstration of distinct subgroups of patients with different IL-13 expression in ulcerative colitis, with distinct clinical and microbial profiles and discusses implications for therapeutics in the context of previous negative anti-IL13 studies.

Bram Verstockt reports a large, single centre experience of Vedolizumab use in both UC and CD from Leuven, Belgium with interesting findings for endoscopic outcomes as well as therapeutic drug monitoring.

Lara Hart discusses her team’s work capturing faecal calprotectin values in a large cohort of patients with clinically quiescent ulcerative colitis undergoing colonoscopy, and reports test performance for predicting ongoing endoscopic or histologic disease activity.

Julien Verdier reports the work of the team at INSERM, Paris, analysing microRNA expression in faeces and considers the significance of the differences they observed between patients with active disease and controls.

New drugs in IBD